Clinical Trials Directory

Trials / Completed

CompletedNCT02584088

Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation

Status
Completed
Phase
Study type
Observational
Enrollment
80 (actual)
Sponsor
TriHealth Inc. · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Accepted

Summary

* The study primarily aims to evaluate the post ablative endometrium and uterus using transvaginal ultrasound to provide descriptive information as to what may be expected in the 12 months after a NovaSure ablation. Investigators believe this knowledge will help them to determine when to proceed with further evaluation postoperatively or when to counsel patients on expectant management based on ultrasonographic findings. * Secondary aims include correlation of ultrasonographic findings to demographic patient data.

Detailed description

Heavy and irregular menses affects 9-14% of gynecologic patients. Surgical can be employed intervention is sought when medical management fails. Endometrial ablation or desiccation of the endometrium using minimally invasive instruments has been utilized in this scenario. The current mainstay intervention is non-resectoscopic radio frequency ablation. These procedures have high satisfaction rates (81 to 93%) similar to hysterectomy and leave up to 47% of patients amenorrheic. Post operative complications, both short and long term, and failure rates have been well studied. A limited number of studies have been performed to assess the histologic state of the post ablative endometrium and fewer assessing the radiographic appearance of the endometrium. Therefore, this current study aims to describe the ultrasonographic appearance of the post ablative endometrium and uterus.

Conditions

Interventions

TypeNameDescription
OTHERUltrasoundThe appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.

Timeline

Start date
2016-10-11
Primary completion
2021-11-01
Completion
2021-11-01
First posted
2015-10-22
Last updated
2022-12-02

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02584088. Inclusion in this directory is not an endorsement.